An oily, sustained counter-regulatory response to TB

Christopher L. Karp, Andrea M. Cooper


**Commentary**

Lipoxins are potent antiinflammatory lipid mediators that restrain and promote the resolution of a wide variety of inflammatory processes. Recent studies implicating deficient lipoxin production in the pathogenesis of diverse inflammatory diseases, along with numerous reports of the beneficial effects of lipoxin analog administration in animal models of inflammatory pathology, have suggested that harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic promise. In this issue of the *JCI*, Bafica et al. address the other side of the coin, reporting that endogenous lipoxins compromise immune-mediated control of *Mycobacterium tuberculosis* infection in mice. In addition to providing novel insight into the mechanisms that interfere with the development of protective immune responses to *M. tuberculosis*, the study raises the possibility that pharmacological inhibition of lipoxin synthesis may provide a method of augmenting inefficient immune responses in TB and other important chronic infectious diseases.

Find the latest version:

http://jci.me/25353/pdf
Lipoxins are potent antiinflammatory lipid mediators that restrain and promote the resolution of a wide variety of inflammatory processes. Recent studies implicating deficient lipoxin production in the pathogenesis of diverse inflammatory diseases, along with numerous reports of the beneficial effects of lipoxin analog administration in animal models of inflammatory pathology, have suggested that harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic promise. In this issue of the JCI, Bafica et al. address the other side of the coin, reporting that endogenous lipoxins compromise immune-mediated control of Mycobacterium tuberculosis infection in mice (see the related article beginning on page 1601). In addition to providing novel insight into the mechanisms that interfere with the development of protective immune responses to M. tuberculosis, the study raises the possibility that pharmacological inhibition of lipoxin synthesis may provide a method of augmenting inefficient immune responses in TB and other important chronic infectious diseases.

Maintenance of health is critically dependent upon the immune system’s ability to generate a balanced response to a variety of threats, real or perceived. Inflammatory responses of insufficient vigor can allow uncontrolled pathogen replication, events central to the development of malaria, TB, and HIV, the top infectious killers in the world today. On the other hand, excessive or inappropriate inflammatory responses place an equally heavy burden on humanity, being key to the pathogenesis of diverse infectious (e.g., sepsis, fulminant viral hepatitis), autoimmune (e.g., inflammatory bowel disease, multiple sclerosis), allergic (e.g., asthma), or inappropriate inflammatory responses (e.g., atherosclerosis) diseases. It is thus not surprising that there has been considerable experimental, theoretical, and therapeutic interest in the molecular mechanisms that restrain the intensity of inflammatory responses. In addition to the usual suspects, such as cytokines, receptors, intracellular signaling inhibitors, and specialized suppressor cells, endogenous antiinflammatory lipid mediators have recently been recognized as playing an important role.

An oily, sustained counter-regulatory response to TB

Christopher L. Karp1 and Andrea M. Cooper2

1Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 2Trudeau Institute Inc., Saranac Lake, New York, USA.

Lipoxins are potent antiinflammatory lipid mediators that restrain and promote the resolution of a wide variety of inflammatory processes. Recent studies implicating deficient lipoxin production in the pathogenesis of diverse inflammatory diseases, along with numerous reports of the beneficial effects of lipoxin analog administration in animal models of inflammatory pathology, have suggested that harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic promise. In this issue of the JCI, Bafica et al. address the other side of the coin, reporting that endogenous lipoxins compromise immune-mediated control of Mycobacterium tuberculosis infection in mice (see the related article beginning on page 1601). In addition to providing novel insight into the mechanisms that interfere with the development of protective immune responses to M. tuberculosis, the study raises the possibility that pharmacological inhibition of lipoxin synthesis may provide a method of augmenting inefficient immune responses in TB and other important chronic infectious diseases.

Maintenance of health is critically dependent upon the immune system’s ability to generate a balanced response to a variety of threats, real or perceived. Inflammatory responses of insufficient vigor can allow uncontrolled pathogen replication, events central to the development of malaria, TB, and HIV, the top infectious killers in the world today. On the other hand, excessive or inappropriate inflammatory responses place an equally heavy burden on humanity, being key to the pathogenesis of diverse infectious (e.g., sepsis, fulminant viral hepatitis), autoimmune (e.g., inflammatory bowel disease, multiple sclerosis), allergic (e.g., asthma), or inappropriate inflammatory responses (e.g., atherosclerosis) diseases. It is thus not surprising that there has been considerable experimental, theoretical, and therapeutic interest in the molecular mechanisms that restrain the intensity of inflammatory responses. In addition to the usual suspects, such as cytokines, receptors, intracellular signaling inhibitors, and specialized suppressor cells, endogenous antiinflammatory lipid mediators have recently been recognized as playing an important role.

An oily, sustained counter-regulatory response to TB

Christopher L. Karp1 and Andrea M. Cooper2

1Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 2Trudeau Institute Inc., Saranac Lake, New York, USA.

Lipoxins are potent antiinflammatory lipid mediators that restrain and promote the resolution of a wide variety of inflammatory processes. Recent studies implicating deficient lipoxin production in the pathogenesis of diverse inflammatory diseases, along with numerous reports of the beneficial effects of lipoxin analog administration in animal models of inflammatory pathology, have suggested that harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic promise. In this issue of the JCI, Bafica et al. address the other side of the coin, reporting that endogenous lipoxins compromise immune-mediated control of Mycobacterium tuberculosis infection in mice (see the related article beginning on page 1601). In addition to providing novel insight into the mechanisms that interfere with the development of protective immune responses to M. tuberculosis, the study raises the possibility that pharmacological inhibition of lipoxin synthesis may provide a method of augmenting inefficient immune responses in TB and other important chronic infectious diseases.

Maintenance of health is critically dependent upon the immune system’s ability to generate a balanced response to a variety of threats, real or perceived. Inflammatory responses of insufficient vigor can allow uncontrolled pathogen replication, events central to the development of malaria, TB, and HIV, the top infectious killers in the world today. On the other hand, excessive or inappropriate inflammatory responses place an equally heavy burden on humanity, being key to the pathogenesis of diverse infectious (e.g., sepsis, fulminant viral hepatitis), autoimmune (e.g., inflammatory bowel disease, multiple sclerosis), allergic (e.g., asthma), or inappropriate inflammatory responses (e.g., atherosclerosis) diseases. It is thus not surprising that there has been considerable experimental, theoretical, and therapeutic interest in the molecular mechanisms that restrain the intensity of inflammatory responses. In addition to the usual suspects, such as cytokines, receptors, intracellular signaling inhibitors, and specialized suppressor cells, endogenous antiinflammatory lipid mediators have recently been recognized as playing an important role.

An oily, sustained counter-regulatory response to TB

Christopher L. Karp1 and Andrea M. Cooper2

1Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 2Trudeau Institute Inc., Saranac Lake, New York, USA.

Lipoxins are potent antiinflammatory lipid mediators that restrain and promote the resolution of a wide variety of inflammatory processes. Recent studies implicating deficient lipoxin production in the pathogenesis of diverse inflammatory diseases, along with numerous reports of the beneficial effects of lipoxin analog administration in animal models of inflammatory pathology, have suggested that harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic promise. In this issue of the JCI, Bafica et al. address the other side of the coin, reporting that endogenous lipoxins compromise immune-mediated control of Mycobacterium tuberculosis infection in mice (see the related article beginning on page 1601). In addition to providing novel insight into the mechanisms that interfere with the development of protective immune responses to M. tuberculosis, the study raises the possibility that pharmacological inhibition of lipoxin synthesis may provide a method of augmenting inefficient immune responses in TB and other important chronic infectious diseases.

Maintenance of health is critically dependent upon the immune system’s ability to generate a balanced response to a variety of threats, real or perceived. Inflammatory responses of insufficient vigor can allow uncontrolled pathogen replication, events central to the development of malaria, TB, and HIV, the top infectious killers in the world today. On the other hand, excessive or inappropriate inflammatory responses place an equally heavy burden on humanity, being key to the pathogenesis of diverse infectious (e.g., sepsis, fulminant viral hepatitis), autoimmune (e.g., inflammatory bowel disease, multiple sclerosis), allergic (e.g., asthma), or inappropriate inflammatory responses (e.g., atherosclerosis) diseases. It is thus not surprising that there has been considerable experimental, theoretical, and therapeutic interest in the molecular mechanisms that restrain the intensity of inflammatory responses. In addition to the usual suspects, such as cytokines, receptors, intracellular signaling inhibitors, and specialized suppressor cells, endogenous antiinflammatory lipid mediators have recently been recognized as playing an important role.

An oily, sustained counter-regulatory response to TB

Christopher L. Karp1 and Andrea M. Cooper2

1Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 2Trudeau Institute Inc., Saranac Lake, New York, USA.
Counter-regulation by lipoxins and resolvins

Lipoxins are trihydroxytetraene-containing arachidonic acid metabolites that are produced by at least 3 distinct lipoxygenase (LO) pathways, involving interactions among diverse cell types, including leukocytes, epithelia, endothelia, and platelets (Figure 1) (1). Our current understanding of the biologically important counter-regulatory activities of the lipoxins is largely due to the pioneering studies of the Serhan laboratory. Among in vitro activities, lipoxin A₄ (LXA₄) and/or its aspirin-triggered isomer, 15-epi-LXA₄: (a) inhibit neutrophil chemotaxis, adherence, transmigration, and activation; (b) suppress epithelial cell and leukocyte production of diverse chemokines; (c) inhibit IL-12 production by DCS; (d) upregulate monocyte chemotaxis and ingestion of apoptotic neutrophils; and (e) suppress MMP production, while stimulating production of tissue inhibitors of MMPs (1–3). In vivo, lipoxins have been shown to have broad counter-regulatory properties, suppressing proinflammatory responses (preventing neutrophil-mediated damage; promoting the resolution of neutrophil-mediated inflammation), Th2-polarized responses (inhibiting inflammation and airway hyperresponsiveness in experimental asthma), and Th1 responses (suppressing immunopathology during infection with Toxoplasma gondii) alike (1, 4, 5). This is a broad counter-regulatory profile, indeed. This profile, and the numerous reports of the beneficial effects of administering metabolically stable analogs in diverse mouse models of inflammatory pathology (1, 4, 6–10), suggest that harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic promise. Lipoxin therapy may be particularly apt for diseases such as severe asthma and cystic fibrosis, where lipoxin deficiency has been implicated in disease pathogenesis (11–13).

It should also be noted that, in addition to those generated from arachidonic acid, immunoregulatory mediators are also generated from omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid. Study of these latter mediators, named resolvins, is at an early stage, but immunologists (who have tended to pay little more than lip service to the biological importance of lipid mediators) should be aware that, like lipoxins, resolvins appear to have broad antiinflammatory, tissue protective, and catabatic properties (14, 15).

Lipoxin-mediated control of the immune response to M. tuberculosis

In TB, bacterial persistence leads to a prolonged type 1 immune response in the lung that, while limiting bacterial growth, does not eliminate the highly inflammatory bacteria. This balance between bac-
ria and inflammation can be maintained for the life of the human host. However, breakdown leads to tissue damage, bacterial growth, and recrudescence disease. While the factors controlling this prolonged immune response have long been the subject of conjecture, the mechanisms responsible for counter-regulation during TB infection have remained obscure. The data implicating obvious candidates such as IL-10 and TGF-β, while intriguing, have remained associative in nature (16, 17).

In this context, the current report by Bafica et al. (18) demonstrating that lipoxins are key modulators of the immune response to M. tuberculosis is of considerable interest. Murine infection with M. tuberculosis led to significant, 5-LO–dependent production of LXA₄. In turn, infected, 5-LO–knockout mice had increased expression of the type 1 mediators IL-12, IFN-γ, and NO synthase 2 (NOS2) (but not TNF), along with better control of mycobacterial replication and enhanced survival. Notably, systemic treatment of 5-LO knockouts with a metabolically stable LXA₄ analog reversed this enhanced control of mycobacterial replication. Such treatment also suppressed M. tuberculosis antigen–driven splenocyte production of IFN-γ (but, again, not TNF). These data provide clear evidence of biologically important, lipoxin-mediated counter-regulation in experimental TB infection and provide what is believed to be only the second example of host gene ablation leading to better control of experimental infection with this pernicious pathogen, the first being the demonstration of the apparent regulatory role of the IL-27 receptor (19).

The lack of immunopathological consequences attending the upregulation of antimycobacterial immune responses in 5-LO–knockout mice is certainly a very welcome finding. This is not the case with T. gondii: despite improved control of parasite replication, 5-LO knockouts succumb rapidly to the encephalitic consequences of augmented inflammation during the early chronic phase of infection (5). As discussed by Bafica et al. (18), the different effect of 5-LO ablation on the course of these 2 infections likely relates to fundamental differences in the biology of the underlying pathogens. A vigorous Th1 response is necessary to contain infection with the rapidly replicating T. gondii, and such a response is induced in immune-compotent hosts. In contrast, the slowly replicating M. tuberculosis induces a less vigorous type 1 response (16). Removal of lipoxin-mediated counter-regulation leads to better control of pathogen replication in both infections. But this advantage is lost in toxoplasmosis, where the unleashing of the more potent antitoxoplasmal response leads to fatal immunopathology.

Taken together, the data presented by Bafica et al. (18) suggest that pharmacological inhibition of lipoxin synthesis may allow for safe, therapeutic augmentation of the inefficient immune responses observed during TB infection. The presented control data are, perhaps, equally suggestive. LXA₄ analog treatment of infected wild-type mice did not hamper the host response to M. tuberculosis. Similar findings have been presented in the context of experimental infection with T. gondii and Pseudomonas aeruginosa (5, 13). Thus, despite the important counter-regulatory role played by lipoxins, lipoxin analog treatment of lipoxin-sufficient animals does not appear to impair protective immune responses to pathogens, a finding with promise for the development of lipoxin analogs for the therapy of tissue inflammatory diseases.

For those used to the relatively direct relationship between gene and mediator among immune-associated proteins, the complexities of lipid mediator generation can be somewhat daunting. Ablation of 5-LO would be expected to ablate both LXA₄ (and LXB₄) and leukotriene production—anti-inflammatorily and proinflammatory mediators alike. This was indeed found in the current study (18). The overall effect of such ablation is, presumably, a reflection of the differing importance, kinetics, and cellular source of these mediators in the model in question. As for LXA₄ itself, although the enzymatic events required for its generation from arachidonic acid are clear (oxygenation at the C5 and C15 positions), the specific LO enzymes that are necessary in any given context remain to be determined. In addition to redundancy in activity (e.g., both 15-LO and 12-LO can insert oxygen at C15) and cell-type specificity, there are 7 LO genes in the mouse genome. The potential for each of these enzymes to affect the availability and activity of lipid mediators needs to be addressed by careful biochemical study. And even these LOs do not exhaust the possible sources of LXA₄ generation during infection. Both T. gondii and P. aeruginosa encode enzymes with 15-LO activity (20, 21). Is it possible that a similar enzyme is lurking in the M. tuberculosis genome?

It is gratifying to see lipid mediators getting their due in immunopathogenesis. The current study should provide impetus for further mechanistic investigation of the role of counter-regulation by lipid mediators in TB. Important questions left open include whether the altered type 1 immunity observed in 5-LO–deficient mice is primarily a reflection of alterations in innate or adaptive immune responses, what enzymes and cells are critical for lipoxin production in this model, and what role the resolvins play in TB. There’s much to be learned.

Acknowledgments

The authors thank N. Petasis for helpful discussions.

Address correspondence to: Christopher L. Karp, TCHRF 1566, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA. Phone: (513) 636-7608; Fax: (513) 636-5355; E-mail: chris.karp@chmmcc.org.

Anorexia is one of several abnormalities characterizing chronic kidney disease (CKD) that cause cachexia, the loss of muscle and adipose stores. It has been attributed to mechanisms ranging from accumulation of toxic "middle molecules" to psychological problems. In this issue of the JCI, Cheung and coworkers used elegant techniques to demonstrate that CKD-associated anorexia is caused by defective hypothalamic regulation of appetite (see the related article beginning on page 1659). They attributed the defect to an alteration in the hypothalamus’s response to leptin and inflammation. Since similar hypothalamic defects suppress appetite in inflammatory states and in cancer, it is possible that anorexia in several cachexia-inducing conditions results from a common set of hypothalamic abnormalities. The development of small molecules capable of preventing these regulatory abnormalities holds the promise of eliminating the contribution of anorexia to the development of cachexia.

The explosion of information emerging from several fields, including molecular and cellular biology and neuroscience, has helped elucidate specific mechanisms that regulate appetite. A major impetus for investigating why we eat is the increasing prevalence of obesity. However, there is a flip side: we also need to understand how catabolic conditions cause anorexia, which can contribute to cachexia — the loss of fat and protein stores. In chronic kidney disease (CKD) there is evidence that the intake of calories, including protein, decreases as renal insufficiency advances (1). Although this is one reason for weight loss in CKD patients, metabolic abnormalities other than poor diet can also cause cachexia (2).

Early studies of the anorexia associated with CKD established a link between this condition and the circulation of “middle molecules” — compounds with molecular weights between 1.0 and 5.0 kDa. While the structures of these anorexigenic middle molecules are unknown, injection of a mixture of them into a normal rat’s peritoneal cavity has been shown to decrease carbohydrate intake (3). Other potential causes of anorexia in CKD patients include a decreased ability to distinguish flavors (i.e., abnormal taste), stomach irritation caused by medicines such as iron compounds or phosphate binders, hemodynamic instability as a result of exposure to antihypertensive medicines or hemodialysis, and a sensation of fullness during peritoneal dialysis, as well as psychological and economic factors.

How does the central nervous system integrate hunger and satiety?

A study by Cheung and colleagues reported in this issue of the JCI (4) provides a quantum increase in our understanding of CKD-associated anorexia. Using animal models of CKD, the authors uncovered defects in the complex neuroendocrine pathways that regulate food intake. To appreciate the scope of their studies, a brief background is needed (see Figure 1). For over 50 years, it has been recognized that inhibitory signals proportional to body fat stores act to decrease food intake (5). The so-called long-term regulators of appetite — insulin and leptin — are produced in the pancreas and adipose cells, respectively. These regulators circulate at levels proportional to body fat and enter the brain in proportion to their plasma levels. In the hypothalamus, they influence neural pathways that integrate feeding and satiety as well as energy expenditure (6, 7). High levels of either leptin or insulin decrease food intake and increase energy expenditure, while low levels stimulate appetite and suppress energy expenditure. There are, however, important differences between the actions of insulin and leptin. A low leptin level increases fat accumulation, which ultimately raises cir-

cachexia in chronic kidney disease
a link to defective central nervous system control of appetite

William E. Mitch
Nephrology Division, Baylor College of Medicine, Houston, Texas, USA.

Nonstandard abbreviations used: AGRP, agouti-related peptide; AMPK, AMP-activated protein kinase; CKD, chronic kidney disease; MC4-R, melanocortin receptor 4; α-MSH, α-melanocyte-stimulating hormone; NPY, neuropeptide Y; POMC, pro-opiomelanocortin; PYY3–36, peptide YY3–36.